NexImmune, Inc.
NEXI · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.03 | -0.34 |
| FCF Yield | -1,351.14% | -896.33% | -45.74% | -4.73% |
| EV / EBITDA | 0.03 | 0.46 | -1.52 | -21.42 |
| Quality | ||||
| ROIC | -800.38% | 1,557.16% | -64.59% | -869.84% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.82 | 0.90 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 39.98% | -8.96% | -76.52% | -31.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.55 | 0.62 | -0.51 |
| Interest Coverage | 0.00 | 0.00 | -58.82 | -16.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -475.87 | -580.30 | -438.34 | -1,627.57 |